Janssen Biotech Inc.

07/02/2024 | Press release | Distributed by Public on 07/02/2024 20:34

CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study